CHICAGO, December 09, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been ...
The UAB Office of Service Learning and Undergraduate Research connects students, faculty, and community nonprofit partners to enrich student academic learning, promote civic engagement, and to ...
Get any of our free daily email newsletters — news headlines, opinion, e-edition, obituaries and more. Ghassane Moutaoukil, a Montana State University graphic design graduate, has found himself in the ...
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
For more information about the event, please visit the meeting website. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of ...
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in ...
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase ...
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback